

RECEIVED  
CENTRAL FAX CENTER

001

OCT 29 2004

**SCHERING-PLOUGH CORPORATION**  
**LAW DEPARTMENT**  
**2000 GALLOPING HILL ROAD**  
**K-6-1, MAIL STOP 1990**  
**KENILWORTH, NEW JERSEY 07033**  
**(908) 298-4000**

**FACSIMILE TRANSMITTAL SHEET**

TO:	FAX NUMBER:
US Patent and Trademark Office Attn: Examiner Deepak R. Rao	(703) 872-9306
FROM:	PHONE NUMBER:
Anita W. Magatti	(908) 298-5067
TOTAL NO. OF PAGES INCLUDING COVER	DATE
29	October 29, 2004

**CONFIDENTIALITY NOTE:** This sheet and/or the document(s) accompanying it contain information belonging to Schering-Plough Corporation and/or its affiliates which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named above. If you have received this fax in error, please immediately notify us by telephone. If there is a problem with this transmission please call Rosa Scasso-Viola at (908) 298-4080.

## NOTES/COMMENTS:

In re application of: Bernard R. Neustadt *et al.*  
 For the Patent Entitled: 2-Alkynyl- and 2-Alkenyl-Pyrazolo-[4,3-e]-1,2,4-Triazolo-[1,5-c]-Pyrimidine Adenosine A<sub>2A</sub> Receptor Antagonists

Filed: 04/21/2004  
 Attorney Docket No.: CN06055US01  
 Serial No.: 10/829,416

Transmitted herewith are:

- Supplementary Information Disclosure Statement (2 pgs.)
- Transmittal of Information Disclosure Statement Pursuant to 37 C.F.R. 1.97(c) OR (d)  
(2 pgs.) in duplicate
- Certificate of Transmission under 37 C.F.R. 1.8 (1 pg.)
- Form PTO-1449 (1 pg.) - In duplicate
- Reference - (BS) - (13 pgs.)
- Reference - (BT) - (6 pgs.)
- Fax Cover Sheet (1 pg.)

  
 Anita W. Magatti  
 Reg. No. 29,825

Attorney Docket No.: CN06055US01

Application No.: 10/829,416

Filing Date: 04/21/2004

First Named Inventor: Bernard R. Neustadt et al.

PTO/SB/07 (08-03)

Approved for use through 07/21/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. 703-872-9306 )

on 10/29/2004

Date



Signature

Anita W. Magatti, Reg. No. 29,825

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Document(s) being transmitted:

Supplemental Information Disclosure Statement (2 pgs.)

Transmittal of Information Disclosure Statement Pursuant to 37 C.F.R. 1.97(c) OR (d) (2 pgs.) in duplicate  
Certificate of Transmission under 37 C.F.R. 1.8 (1 pg.)

Form PTO-1449 (1 pg.) -in duplicate

Reference - (BS) - (13 pgs.)

Reference - (BT) - (6 pgs.)

Fax Cover Sheet (1 pg.)

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED  
CENTRAL FAX CENTER

2003

OCT 29 2004

PATENT  
Case: CN06055US01IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Bernard R. Neustadt et al

For Patent For:  
2-Alkynyl- and 2-Alkenyl-Pyrazolo-[4,3-e]- :  
1,2,4-Triazolo-[1,5-c]-Pyrimidine  
Adenosine A<sub>2a</sub> Receptor Antagonists : Examiner: Deepak R. Rao  
Art Unit: 1624

Serial No.: 10/829,416

Filing Date: April 21, 2004

Schering-Plough Corporation  
Kenilworth, New Jersey 07033-0530

Commissioner for Patents  
PO Box 1450  
Alexandria VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. 1.97(c) OR (d)

Sir.

37 C.F.R. 1.97(c)

- 1.a.  The information disclosure statement transmitted herewith is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
- (1) a final action under § 1.113, or
  - (2) a notice of allowance under § 1.311, whichever occurs first.
- 1.b.  This statement is accompanied by the certification set forth below. OR
- 1.c.  Applicant(s) elect to pay the fee of \$180.00 for the submission of this information disclosure statement.

Certificate of Transmission

I hereby certify that this correspondence is being facsimile  
transmitted to the Patent and Trademark Office (Fax No. 703-872-9306) on  
October 29, 2004,  
(Date)

Typed or printed name of person signing this certificate.

Anita W. Magatti  
(name)

Signature

Page 2

37 C.F.R. 1.97(d)

- 2.a.  The information disclosure statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.
- 2.b.  This statement is accompanied by the certification set forth below. AND
- 2.c.  Applicant(s) hereby petition for the consideration of the accompanying information disclosure statement. AND
- 2.d.  The fee for this petition is \$130.00.

METHOD OF PAYMENT

- 3.a.  Charge \$ 180.00 to Deposit Account No. 19-0365.
- 3.b.  The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0365. (in duplicate)

CERTIFICATION

4.  I, the person signing below, hereby certify
  - that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
  - that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months prior to the filing of the statement.

Name \_\_\_\_\_

Signature \_\_\_\_\_

Date \_\_\_\_\_

Respectfully submitted,

  
Anita W. Megatti  
Attorney/Agent for Applicant(s)  
Registration No.: 29,825  
Telephone No.: (908) 298-5067

SCHERING-PLOUGH CORPORATION  
Patent Department, K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, New Jersey 07033-0530  
Date: October 29, 2004

Rev. 11/96 JS

RECEIVED  
CENTRAL FAX CENTER

OCT. 29 2004

PATENT

CASE CN06055US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of:  
Bernard R. Neustadt et alFor Patent For:  
2-Alkynyl- and 2-Alkenyl-Pyrazolo-[4,3-e]- :  
1,2,4-Triazolo-[1,5-c]Pirimidine  
Adenosine A<sub>2a</sub> Receptor Antagonists : Examiner: Deepak R. Rao  
Art Unit: 1624

Serial No.: 10/829,416

Filing Date: April 21, 2004

Schering-Plough Corporation  
Kenilworth, New Jersey 07033-0530Commissioner for Patents  
PO Box 1450  
Alexandria VA 22313-1450SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This statement is made in compliance with 37 C.F.R. 1.56, 1.97 and 1.98.

Applicants submit a Form PTO-1449 (1 page) listing additional publications known to applicants that may be relevant to this application.

Publications BA, BS and BT were cited in the International Search Report of corresponding application PCT/US04/012471, filed April 21, 2004. The Search Report also cited WO 01/92264, previously cited by applicants, which is equivalent to publication BA. All were designated "A," indicating the general state of the art.

Copies of BS and BT are enclosed; as indicated, BA is equivalent to a previously-provided publication, so no additional copy is provided.

**Certificate of Transmission**I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office (Fax No. 703-872-9306) on October 29, 2004,

(Date)

Typed or printed name of person signing this certificate.


Anita W. Magatli  
(name)

Signature

-2-

The examiner is requested to examine the publications, to initial the form PTO-1449 and to return a copy of the initialed form to applicants.

Respectfully submitted,

  
Anita W. Magatti  
Reg. No. 29,825  
Attorney for Applicants  
(908) 298-5067

Sheet 1 of 1

FORM PTO-1449 <b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b> <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO.: CN06055US01	SERIAL NO.: 10/829,416	
				APPLICANT: Bernard R. Neustadt et al		
				FILING DATE: April 21, 2004	GROUP: 1624	
<b>U.S. PATENT DOCUMENTS</b>						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
BA	2002/099061	7/25/02	Neustadt et al	514		
BB						
BC						
BD						
BE						
BF						
BG						
BH						
<b>FOREIGN PATENT DOCUMENTS</b>						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES      NO
BL						
BM						
BN						
BO						
BP						
BQ						
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
BS	Baraldi et al, J. Med. Chem., 43 (2000) 4768-80					
BT	Baraldi et al, Bioorganic and Med. Chem. Let., 4 (21) (1994) 2539-44					
BU						
BV						
BW						
EXAMINER			DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						